SEC Form 4 · accession 0001171843-15-004973
Sucampo Pharmaceuticals, Inc. · SCMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel P Getman
Director
Period of report
Aug 28, 2015
Accepted (ET)
Aug 31, 2015 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001365216
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Aug 28, 2015 | M | 30,000 | $3.20 | A | 30,000 | D | |
| Class A Common StockF1 | Aug 28, 2015 | S | 30,000 | $28.14 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F2 | $3.20 | Sep 1, 2011 | M | 30,000 | D | — | Sep 1, 2021 | Class A Common Stock | 30,000 | 80,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.865 to $28.49, inclusive. The reporting person undertakes to provide Sucampo Pharmaceuticals, Inc., any security holder of Sucampo Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2Vesting commenced on December 1, 2011 in 12 equal quarterly installments.